Biotechnology Press Release
|06/12/2020 - 12:35||
New Efficacy and Biomarker Data From Rivipansel Phase 3 RESET Trial to Be Presented at Sickle Cell Meeting
This analysis and new biomarker data will be presented at the September meeting of the Foundation for Sickle Cell Disease Research (FSCDR). In addition to the rivipansel poster, an abstract containing data on GlycoMimetics’ more selective and highly potent E-selectin antagonist, GMI-1687, has been accepted for an oral presentation.
|06/12/2020 - 11:23||
CSL Behring to Attend and Sponsor World Federation of Hemophilia First Ever Virtual Summit
KING OF PRUSSIA, Pa - June 12 2020 - Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) first ever Virtual Summit June 14-19, 2020. WFH is an international not-for-profit organization that works to improve the lives of people with hemophilia and other inherited bleeding disorders, and CSL Behring is proud to be a long-term partner with the WFH to connect the global bleeding disorders community.
|06/11/2020 - 07:03||
Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference
Presentation Information: Date: Thursday, June 18, 2020 Time: 3:40 PM ET Webcast: A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.cidara.com .
|06/11/2020 - 03:55||
Rigel to Present Poster Highlighting TAVALISSE at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress
SOUTH SAN FRANCISCO, Calif., June 11, 2020 / / -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE ® (fostamatinib disodium hexahydrate) tablets will be highlighted in a presentation at the Virtual Edition of the 25 th EHA Annual Congress taking place June 11-21, 2020. The presentation will be made available on the event's website at www.ehaweb.org/congress/ on Friday, June 12 at 8:30 am CEST.
|06/11/2020 - 03:10||
BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1 Synthesized by AMRI
Under the first agreement, Neurotrope will transfer to BryoLogyx the right to develop bryostatin‑1 for the potential treatment of CD22+ B-cell acute lymphoblastic leukemia (ALL). Relapsed ALL in CD22 CAR-T treated patients has been associated with reduced CD22 antigen density. Bryostatin-1 has been shown to increase CD22 expression levels in leukemia patients, and in a mouse model, resulted in improved treatment response and durability. Neurotrope will also transfer to BryoLogyx the Investigational New Drug (“IND”) application that is in development.
|06/10/2020 - 13:54||
Coronavirus (COVID-19) Update: FDA Authorizes First Next Generation Sequence Test for Diagnosing COVID-19
The FDA authorized the Illumina COVIDSeq Test for the qualitative detection of SARS-CoV-2 RNA from respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider. Using next generation sequencing means that the test can generate information about the genomic sequence of the virus present in a sample, which can be also used for research purposes.
|06/10/2020 - 12:23||
Catalent Partners with Spicona to Develop COVID-19 Vaccine Candidate Using GPEx Cell Line Development Platform
NEW YORK and SOMERSET, N.J. – June 10, 2020 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has signed an agreement with Spicona, Inc.
|06/09/2020 - 14:56||
Governor Cooper Announces Major Expansion by Grifols Bringing 300 New Jobs to Johnston County
Grifols Therapeutics, the global healthcare company, will expand its North Carolina operations with a new $351.6 million capital investment, creating 300 jobs, Governor Roy Cooper announced today. The company will construct a specialized blood plasma facility and logistics center at its Clayton campus in Johnston County.
|North Carolina ...|
|06/09/2020 - 14:39||
City of Hope scientists showcase new findings at the 2020 AACR Virtual Annual Meeting II
DUARTE, Calif. — City of Hope scientists will showcase research at the AACR Virtual Annual Meeting II that could one day lead to real-time diagnostic imaging and leading-edge genomic profiling that improve health outcomes for cancer patients, and much more.
|City of Hope Na...|
|06/09/2020 - 08:56||
Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
A live webcast of the fireside chat will be available by visiting the "Investors" section of the company's website: www.relmada.com . A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.
|06/09/2020 - 06:34||
Global Spices and Seasonings Market Overview 2020: Growth, Demand and Forecast Research Report to 2025
According to the latest report by IMARC Group titled, “Spices and Seasonings Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025”, the market to exhibit a CAGR of around 4% during 2020-2025.
|06/08/2020 - 23:18||
Illumina Receives First FDA Emergency Use Authorization for a Sequencing-Based COVID-19 Diagnostic Test
SAN DIEGO--( )-- Illumina, Inc. (NASDAQ: ILMN) is paving the way for large-scale, next-generation sequencing-based (NGS) COVID-19 testing. Today, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Illumina COVIDSeq™ Test, a high-throughput, sequencing-based, in vitro diagnostic (IVD) workflow enabling the detection of SARS-CoV-2. The end-to-end workflow extends the options available for labs to scale diagnostic testing.
|06/08/2020 - 14:35||
CSL Behring to Acquire Biotech Company Vitaeris
KING OF PRUSSIA, Pa. – 8 June 2020 – Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Vitaeris Inc., a clinical-stage biotechnology company focused on the phase III development of clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAB), for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients.
|06/08/2020 - 14:06||
Davis Polk Advises Clarivate Plc on $1.08 Billion Offering of Its Ordinary Shares
Davis Polk advised Clarivate Plc in connection with the $1.08 billion SEC-registered offering of 48,000,000 of its ordinary shares, of which 14,000,000 ordinary shares were issued and sold by Clarivate and 34,000,000 ordinary shares were sold by affiliated shareholders of Onex Corporation and Baring Private Equity Asia (BPEA) and certain other shareholders. The ordinary shares are listed on the New York Stock Exchange under the symbol “CCC.”
|06/08/2020 - 09:30||
Biodesix Launches COVID-19 WorkSafe Employer Testing Program
BOULDER, CO, June 8, 2020 - Biodesix, Inc., a leading diagnostic company in lung disease, announced today that it has launched the Biodesix WorkSafe™ Program, a customized return to work service for employers. The program is designed to help all businesses in the U.
|06/08/2020 - 05:01||
CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program
Wei-Wu He, Ph.D., CASI’s Chairman and Chief Executive Officer, commented, “Submitting this CTA is an important step in the clinical development of this promising therapy in our hematology oncology franchise. CID-103 demonstrated encouraging efficacy in preclinical models and we believe it has the potential to be best in class and can offer meaningful clinical benefits over the standard of care for patients with CD38 malignancies, including multiple myeloma.”
|06/08/2020 - 04:44||
Wade Ackerman and Amy Toro Named Top Health Care Lawyers
LOS ANGELES —Daily Journal has named Wade Ackerman and Amy Toro to its 2020 Top Health Care Lawyers, a recognition of the leading California lawyers who specialize in health care litigation, transactions, and counselling.
|06/04/2020 - 14:41||
Catalents Chair and CEO, John Chiminski, to Speak About R&D Leadership Through the Pandemic During BIO Digital
SOMERSET, N.J. – June 4, 2020 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that John Chiminski, Chair and Chief Executive Officer, will join other R&D leaders to present during BIO Digital, which will take place on June 8 – 12, 2020.
|06/04/2020 - 13:36||
Halozyme Announces Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX Utilizing Halozyme's ENHANZE Technology For The Treatment Of Patients With Multiple Myeloma
The approval follows a Positive Opinion by the CHMP of the European Medicines Agency (EMA) in April 2020. The SC formulation is administered as a fixed-dose over approximately three to five minutes, significantly less time than IV DARZALEX ® , which is given over several hours. Patients currently on IV DARZALEX ® will have the choice to switch to the SC formulation.
|06/04/2020 - 12:31||
FDA PROVIDES 510(k) CLEARANCE FOR BAUSCH + LOMB INFUSE DAILY DISPOSABLE SILICONE HYDROGEL (SiHy DAILY) CONTACT LENSES
BRIDGEWATER, N.J., June 4, 2020 – Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc.
|Bausch and Lomb|
|06/04/2020 - 07:22||
Mylan and Lupin Receive European Marketing Authorization for Nepexto, Biosimilar Etanercept
HERTFORDSHIRE, England , PITTSBURGH and MUMBAI, India , June 4, 2020 / / -- Mylan N.V. (NASDAQ: MYL) and Lupin Limited (Lupin) today announced that the European Commission (EC) has granted marketing authorization for Nepexto ® , a biosimilar to Enbrel ® (etanercept), for all indications of the reference product including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.
|06/03/2020 - 17:18||
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
William Blair 40 th Annual Growth Stock Conference : Exelixis is scheduled to present at 11:40 AM EDT / 8:40 AM PDT on Tuesday, June 9, 2020 . Goldman Sachs 41st Annual Global Healthcare Conference: Exelixis is scheduled to present at 2:10 PM EDT / 11:10 AM PDT on Wednesday, June 10, 2020 . BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference : Exelixis is scheduled to present at 4:00 PM EDT / 1:00 PM PDT on Tuesday, June 23, 2020 .
|06/03/2020 - 07:52||
Rigel to Present Four Posters Highlighting IRAK1/4 Inhibitor at the EULAR 2020 E-Congress
SOUTH SAN FRANCISCO, Calif., June 3, 2020 / / -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to R835, the company's investigational IRAK1/4 inhibitor, will be presented in two oral and two poster presentations at the European League Against Rheumatism (EULAR) 2020 E-Congress taking place June 3-6, 2020. A fifth abstract highlighting R835 has been accepted for publication. The presentations will be made available on the event's website at https://congress.eular.org/ on Wednesday, June 3 at 1:00 AM CEST.
|06/02/2020 - 17:00||
NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax-L for Glioblastoma Brain Cancer
BETHESDA, Md., June 2, 2020 – Northwest Biotherapeutics (OTCQB: NWBO)(“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported progress toward data lock for the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer.
|06/02/2020 - 11:58||
Governor Cooper Announces Nearly 400 New Jobs in Durham as Multi-Cancer Early Detection Company Chooses New Laboratory Location
GRAIL, Inc. ., an innovative healthcare company pioneering a test that detects more than 50 cancers with a single blood draw, will invest $100 million and over time create 398 new jobs in Durham, Governor Roy Cooper announced today. The project will bring a new state-of-the-art laboratory facility with office and warehouse space to North Carolina’s Research Triangle Park.
|North Carolina ...|